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Abstract
Background: Vanuatu was formerly highly endemic for lymphatic filariasis (LF), caused by Wuchereria bancrofti and
transmitted by Anopheles mosquitoes. After a baseline survey showing 4.8% antigen prevalence in 1998, the country
conducted nationwide (in one implementation unit) annual mass drug administration (MDA) with albendazole and
diethylcarbamazine citrate from 2000 to 2004 and achieved prevalence of 0.2% by 2006 in a representative
nationwide cluster survey among all age groups.
Methods: Post MDA surveillance was conducted from 2006 to 2012. After MDA, the country was divided for
surveillance into three evaluation units (EUs) formed by grouping provinces according to baseline prevalence: EU1:
Torba, Sanma and Malampa; EU2: Penama; EU3: Shefa and Tafea. The study compiled all past data and information
on surveys in Vanuatu from the country programme. This paper reviews the surveillance activities done after stopping
MDA to validate the interruption of transmission and elimination of LF as a public health problem.
Results: Post-MDA surveillance consisting of at least three transmission assessment surveys (TAS) in each of the three
EUs was conducted between 2006 and 2012. Sentinel and spot check surveys identified a few villages with persistent
high prevalence; all antigen positive cases in these sites were treated and additional targeted MDA conducted for
3 years in 13 villages in one area of concern. All three EUs passed all TAS in 2007, 2010 and 2012
respectively, with no positives found except in EU2 (Penama province) in 2012 when 2 children tested
positive for circulating filariasis antigen. Assessment of the burden of chronic filariasis morbidity found 95
cases in 2003 and 32 remaining cases in 2007, all aged over 60 years.
Conclusions: Vanuatu has achieved validation of elimination of LF as a public health problem. Post-validation
surveillance is still recommended especially in formerly highly endemic areas.
Background
Vanuatu is a Pacific Island nation and one of the 16 Pacific
Island countries and territories included in the Pacific
Programme to Eliminate Lymphatic Filariasis (PacELF)
started in 1999 [1, 2]. PacELF is part of the Global
Programme to Eliminate Lymphatic Filariasis (GPELF)
which was launched in 2000 and aims to eliminate
lymphatic filariasis (LF) as a public health problem by
2020 [3]. Elimination as a public health problem in this
context includes interruption of transmission by mosqui-
toes and provision of services for those suffering from
acute and chronic LF morbidity (acute attacks of lymph-
angitis, lymphoedema/elephantiasis and hydrocele).
Vanuatu is known to have been highly endemic for LF,
based on a few surveys conducted prior to 1997, which
have been reviewed in [4]. Some control efforts using
mass drug administration (MDA) for up to 3 years in
seven islands did not succeed in interrupting
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transmission [5]. At the start of the PacELF control
programme in Vanuatu in 1999, the national LF antigen
prevalence measured by immunochromatographic test
(ICT) was estimated to be 4.8% in a baseline survey of
51 villages. Through intense efforts of annual MDA
campaigns combining albendazole and diethylcarbama-
zine citrate (DEC) with vector control, antigen preva-
lence was reduced to 0.2% by 2006 as estimated in a
survey of 90 household clusters. Programme implemen-
tation and MDA campaigns from 2000 until the final
round of MDA in 2004 and the stop MDA survey in
2006 have been previously reported [4]. The current
paper reviews the monitoring and post-MDA surveil-
lance activities (including spot check site surveys after
2004) as evidence towards validation of elimination of
LF as a public health problem according to current
WHO validation process [6]. Available information on
morbidity is also included in the present paper.
The monitoring and surveillance framework
GPELF 2000 guidelines: Initially the Vanuatu LF
programme followed the first (2000) GPELF guidelines
[7]. These called for a mapping survey to assess LF
endemicity in designated implementation units, testing
of at least two sentinel sites and two spot check sites at
baseline before the first round of MDA and during
MDA, and, after achieving a microfilariae (Mf) preva-
lence rate of less than 1% in these sites, performing a lot
quality assurance sampling (LQAS) survey of 3000
children aged 6–10 years, born after the initiation of
effective MDA rounds. The LQAS survey was designed
to determine whether further MDA rounds can be
stopped using a cut-off of <0.1% circulating filariasis
antigen (CFA) prevalence.
PacELF 2003 guidelines: Due to small population sizes
of some Pacific Island countries and the lack of tests
able to determine such a low level cut-off, the PacELF
developed its own monitoring and evaluation (M&E)
framework in 2003 and 2004 for assessing interruption
of transmission [1]. This framework stipulated a com-
munity cluster survey of all ages, and MDA to be
stopped if antigen prevalence was <1%. In the PacELF
terminology, the baseline survey was A, the sentinel site
surveys B, and the stop MDA survey was the C survey.
The D survey was the LQAS survey among children as
proposed by the GPELF.
Modified 2005 GPELF guidelines: In 2005, the GPELF
published the revised M&E guidelines [8] which recom-
mended increased numbers of sentinel and spot check
surveys be conducted before the fifth MDA to determine
whether the Mf prevalence in all of the sampled sites
was <1%. To determine whether MDA should be
stopped, the LQAS survey of 3000 children was retained,
but the recommended age group was changed to school
entrants. However, Vanuatu was already in the process
of conducting a C survey in all age groups in 2005 [4],
rather than following the 2005 GPELF guidelines.
Modified PacELF 2008 guidelines: In 2007, the
PacELF proposed a new surveillance framework that
was modified in 2008 [9] for the Pacific countries,
including Vanuatu. These guidelines retained the
community-based cluster C survey in all ages for the
stopping MDA decision with a threshold of 1% anti-
gen prevalence but modified the D survey to a child
transmission survey (CTS). The CTS had a target
sample size of all children aged 5 in a country (with
the exception of PNG), to detect antigen positive
children, either in school or community-based sur-
veys. An additional action component included was
the tracing of contacts of any cases who were positive
for CFA (by ICT) or Mf, by testing surrounding resi-
dents within 200 m or the nearest 24 houses to the
index child’s place of residence. Vanuatu adopted this
approach and conducted a nationwide CTS in 2007.
The 2008 PacELF framework used in Vanuatu was imple-
mented to some extent in other Pacific countries.
GPELF 2011 guidelines: The modified PacELF
framework used until 2008 was then superseded by
the new WHO-recommended protocol for transmis-
sion assessment surveys (TAS) [10] which was the
procedure followed by Vanuatu for subsequent post-MDA
surveys after 2010. PacELF followed these guidelines for
TAS after 2008.
Methods
LF programme timeline
Table 1 shows the summarised timeline of activities
between 1997 and 2012, including specific timing of
post MDA surveillance and follow-up activities described
in this paper.
Following the baseline survey in 1997 and 1998,
annual MDA rounds were conducted for five consecu-
tive years nationwide during 2000–2004, with reported
national coverage rates of 83, 84, 84, 87 and 85% re-
spectively [1, 4, 11]. Sentinel site B surveys were started
in eight villages in 2002 [12]. Spot-check site surveys
were also initiated in several villages and hospitals
between 2002 and 2004 during the MDA period [4]. The
last MDA was conducted in 2004, and the C survey was
done in 2005–2006 (together with sentinel sites and
additional spot-check site surveys), and CTS or TAS
surveys in 2007, 2010 and 2012.
Results
Sentinel and spot-check site surveys and targeted MDAs
As reported previously and summarised in Table 2 [4],
there were six sentinel sites (two each in Torba, Sanma
and Penama provinces) that were surveyed in 1997/
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1998, 2002 and 2006. Two additional sentinel sites in
Malampa province were surveyed in 1997/1998 and
2002 only. The names of these eight sentinel site villages
are shown in italics in Table 2. All sentinel sites showed
a decline in CFA prevalence over time, and five of the
six sites had reached 0% CFA prevalence by 2006. The
remaining site with persistent positives was Wanur in
South Pentecost, Penama province. The locations of the
sentinel sites are indicated in Fig. 1.
Some additional villages were sampled as spot-check
sites, some of them more than once, from 2002 onwards.
These surveys are also compiled in Table 2, with
locations of the sites indicated in Fig. 1. The surveys
tested all age groups, with additional tests done on 3–
6 year olds or 6–7 year olds in certain villages, as shown
as footnotes to the table.
It can be noted from Fig. 1 that North Ambrym (1999
census population 3899) and South Pentecost (2000
estimated population 2222) are located close to each
other, despite being in different provinces and evaluation
units (EUs). North Ambrym was identified as an area of
concern due to remaining high prevalence in 2004 from
spot-check site surveys, and Maewo and South Pente-
cost in 2005–2006 through spot-check sites done in
Table 1 Surveillance activities in Vanuatu, 1997–2012
Year M&E activity Detail and location by province or evaluation unit (EU)
1997–1998 Mapping survey: baseline A survey Nationwide, 51 villages
2000 The first year of MDA Nationwide
2002 Sentinel site B surveys Torba, Sanma, Malampa, Penama, 2 villages each
Spot checks 1 village Malampa, 1 village Penama, 2 hospitals
2003 Spot checks 4 hospitals
Morbidity assessment Nationwide
2004 The last year of MDA Nationwide
Spot checks 15 villages, North Ambrym, Malampa
2005 To 2006 Stop MDA survey
C survey/TAS 1 (all ages)
Nationwide in 30 villages per EU
EU1 (Torba, Sanma, Malampa);
EU2 (Penama);
EU3 (Shefa and Tafea)
Sentinel sites Torba, Sanma, Penama (2 villages each).
Spot checks 6 villages of Penama (EU2)
2007 Transmission assessment survey
D survey/CTS/TAS 2
Community TAS 2 in 6–7 year olds
EU1 (Torba, Sanma, Malampa);
EU2 (Penama);
EU3 (Shefa and Tafea)
Morbidity assessment Malampa and parts of Penama, Sanma, Shefa, Tafea
2008 Spot checks 5 villages of South Pentecost and West Ambae (Penama, EU2)
Targeted MDAa and spot checks Targeted follow-up MDA round 1: 13 villages of North Ambrym,
Malampa province (in EU1)
Spot checks followed MDA
2009 Targeted MDA Targeted follow-up MDA round 2: North Ambrym, Malampa
province (in EU1)
2010 Targeted MDA Targeted follow-up MDA round 3: North Ambrym, Malampa
province (in EU1)
Transmission assessment survey
TAS 3
Community TAS 3 in EU1 and 2;
Children tested in 2 spot-check villages in EU3
2011 Spot checks and sentinel sites Vila and Santo Hospitals
USP students
Sentinel sites EU1, EU2, EU3 (2 villages each—test and treat of
former positives only)
2012 Transmission assessment survey
TAS 3 continued
Community TAS 3 in EU3
TAS 4 Community TAS 4 in EU2
Dossier preparation Preparation of elimination dossier started
aIn targeted MDA, treatment without prior testing is offered to all inhabitants >2 yrs of age in selected villages thought to have persistent high prevalence, such
as villages of North Ambrym identified in 2004. See [4] for details
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conjunction with the C survey. Baitora and Nasawa
villages (in Maewo) and Beimateli/Londar village (in
south Pentecost) as spot-check sites all had >4% CFA
prevalence in 2006. There was also 6% CFA prevalence
(N = 60) in one village (Vetimboso) surveyed in Torba
province in 2006.
In response to the spot-check site survey results in North
Ambrym in 2004, the programme decided to implement
three additional rounds of targeted MDA (offering
treatment to all village residents) in this area in 2008, 2009
and 2010 with treatment coverage of 76, 78 and 79%. Spot
checks in 2008 covered 13 villages (Konkon, Fantongtong,
Ranvetlam, Ranon, Fona, Olal, Makam, Wilit, Noha,
Nimbul, Nobul, Fanla and Fanrereo) after the first targeted
MDA, and the results showed that CFA prevalence had
dropped from 19.1% in 2004 to 2.3% in 2008 in all age
groups (Table 2). The survey of 188 children aged 3–6 years
in the same area found no CFA positives.
In South Pentecost in 2008, a spot-check survey found
3.9% CFA prevalence in a newly sampled site, Point
Kross. Additional testing of 3 to 6 year olds only was
done in 4 villages in South Pentecost in 2008: Point
Kross, Londar/Baemateli, Namaram and the former
sentinel site Wanur (Table 2), with no CFA positives
detected. Another spot-check site survey (Nanako village
in Ambae) in the same EU showed 0% positive out of
123 tested.
In summary, there were 46 CFA positives detected (32
in North Ambrym and 14 in South Pentecost) whose
ages ranged from 17 to 73 years old in 2008. Eight of the
CFA-positive cases in South Pentecost had been positive
in the baseline survey in 1997/1998. The others had not
been tested until 2005 or 2008. There were no Mf posi-
tives found among those who tested positive for CFA in
any sites surveyed; all CFA positives were treated dir-
ectly after Mf blood slides were collected. Unlike in
North Ambrym, no further MDA was conducted in
Pentecost or Maewo, where villages with persisting
prevalence >1% were discovered in 2005–2006, since
sentinel and spot-check sites had all been offered testing
and treatment if positive; in addition, Penama province
(EU2) received an extra TAS in 2012 (see below).
In 2011, ICT testing (N = 1100) was also conducted
at 2 main hospitals (in Santo and Port Vila) on per-
sons presenting for malaria examinations, and zero
CFA positives were found. As for migrant screening,
the programme tested 101 students who came to
study at the University of South Pacific in Port Vila
from other Pacific Island countries and found zero
CFA positives. The formerly positive persons in all 8
Table 2 Results of sentinel and spot check site surveys by village, 1998–2011
EU Province Island Villagea CFA prevalence by ICT (number tested)
1998 2002 2004 2005/2006 2008 2010
1 Torba Vanua Lava Sola 9.7% (31) 1.2% (165) 0.0% (154)
Mosina 10.7% (28) 4.0% (76) 0.0% (80)
Vetimbuso 6.0% (60)
Malampa Ambrym North Ambrym
13–15 villages
19.1% (551) 2.3% (1368)b
Unmet 52.0% (100) 20.0% (208)
Malekula Lingarak 0.0% (218)
Orap 4.0% (100) 1.3% (224)
2 Penama Ambae Sakau 45.8% (48) 27.2% (92) 0.0% (61)
Redcliffe 39.5% (129) 0.0% (132)
Nanako 0.0% (123)
Maewo Baitora 77.8% (72) 4.8% (84)
Nasawa 20.7% (121) 4.1% (121)
Pentecost Beimateli/ Londar 43.9% (155) 6.1% (213)
Point Kross 3.9% (333)c
Wanur 35.0% (60) 8.6% (58) 2.3% (88)
3 Shefa Efate Ebule 0.0% (91) d
Tafea Tanna Port Resolution 7.1% (98) 1.3% (300) 0.0% (135) 0.0% (50) d
Erromango South River 13.9% (65) 6.2% (65) 0.0% (100)
aOriginal sentinel site villages are shown in italics. In sentinel sites in 2002, only persons aged over 10 years were tested
bAlso tested: 3–6 year olds in 13 North Ambrym villages, 2008: 0.0% (188); only combined data available
cAlso tested: 3–6 year olds in 4 Pentecost villages (Barmateli/Londar, Namaram, Point Kross, and Wanur), 2008: 0.0% (86); only combined data available
dThese surveys done in 6–7 year old children only, as part of TAS 3
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sentinel sites from 2002 to 2008 were also followed
up and retreated if still positive in 2011. There were
2 positive persons found out of 102 tested in all sites
in 2011, and they were both resident in Sakau village
in Penama (EU2) where 23 of the formerly positive
people were tested.
Transmission assessment surveys
The C survey of 2005/2006 is now referred to as TAS 1,
although it was done in all ages rather than children
aged 6–7 years as recommended by the transmission
assessment surveys (TAS) protocol [10]. Results were
presented in [4].
For TAS 2, conducted in November and December
2007, Vanuatu piloted the 2008 revised PacELF guide-
lines; this survey is also referred to as the D survey or
child transmission survey (CTS) in the original [1] and
revised [9] PacELF framework respectively. The CTS/
TAS 2 in 2007 tested 71.9% of the estimated total
number of eligible 6- and 7-year-old children (born
between 1 November 2000 to 31 December 2001) in
three EUs comprising all six provinces as grouped for
the C survey/TAS 1 (estimated N = 6605) through a
community-based approach (Table 3). There were 25
teams in total and 2 to 6 teams were assigned per prov-
ince. The teams covered 86.2% of the target number of
children in EU1, 52.3% in EU2 and 71.8% in EU3. No
CFA positives were found among the 4752 children
tested, aged 6–7 years, giving upper 95% confidence
intervals for CFA prevalence of 0.2% in EU1, 1.0% in
EU2 and 0.3% in EU3 (Table 3). The survey sample
builder software [10] was not used for these surveys, but
no positives were detected so the results were below any
threshold that would have been generated. Thus, in TAS
2, all three EUs passed.
TAS 3 was conducted in 2010 and 2012 under GPELF
2011 guidelines [10]. EU1 and EU2 were surveyed in
2010 using a school-based approach, testing all first
graders in the respective EUs. TAS 3 in EU3 initially
tested only children in one sentinel site (Port Resolution,
Tafea province) and one spot-check village (Ebule, Shefa
province) in 2010. Completion of the TAS 3 in EU3 in
Fig. 1 Division of Evaluation Units (EUs), and locations of sentinel and spot check sites and hospitals. Locations of the sites surveyed between
2002 and 2012 are shown (excluding the C survey 90 villages). The inset shows detail of North Ambrym (Malampa province, EU1) and islands of
Penama province (EU2)
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all other school-aged children was done in 2012. Over
both years combined, 63.2% (77.1% in EU1, 90.1% in
EU2 and 40.8% in EU3) of all 6–7-year-old children in
the three EUs were tested with ICT (estimated total
population N = 7086) (Table 4) and no CFA positives
were found among the 4480 children tested. Despite the
low sampling proportion in EU3, all three EUs passed
the TAS 3 (Table 4), as the results were below the
critical cut-offs (first integer <0.02N, where N is the
estimated population in each EU). The TAS 3 in EU2
was conducted with support from the Task Force for
Global Health, and the results have been published in
summary form [13].
A TAS 4 was performed only in EU2 (Penama province)
in 2012 (Table 5). The estimated total population of 6–7-
year-old children was 1034 in the EU. Two ICT positive
children were found out of 933 tested. The critical cut-off
was 20 and therefore EU2 passed TAS 4 [10]. The results
of the TAS 4 have been published in summary form [13].
Morbidity burden estimates
In 2003, the LF programme attempted to identify all per-
sons with LF morbidity in the country by enlisting
health staff to investigate during the MDA round. A
morbidity survey form was inserted into the 2003 MDA
registration books, and nurses were instructed to record
any morbidity patients in their area on the forms which
were submitted back to the national programme after
the MDA. The resulting estimates are shown in Table 6,
and the numbers and location by island in Fig. 2. A total
of 95 cases were found in 2003, with two thirds being in
males; about one third of cases were hydroceles or
mixed hydroceles, or mixed limb and breast-related
morbidities.
Table 3 Results of TAS 2 in all EUs, 2007
Evaluation unit Province Province 6–7
year old popa
% of 6–7
year pop tested
N tested ICT N ICT positive % ICT positive Upper 95% exact
binomial CI
1 Torba 355 77.2% 274 0 0.0%
Sanma 1305 73.6% 960 0 0.0%
Malampa 1128 86.2% 972 0 0.0%
Total EU1 2788 79.1% 2206 0 0.0% 0.2%
2 Penama 966 52.3% 505 0 0.0%
Total EU2 966 52.3% 505 0 0.0% 1.0%
3 Shefa 1711 86.1% 1473 0 0.0%
Tafea 1140 49.8% 568 0 0.0%
Total EU3 2851 71.6% 2041 0 0.0% 0.3%
Vanuatu total 6605 71.9% 4752 0 0.0% 0.1%
aProjected from 1999 census
Table 4 Results of TAS 3 in all EUs, 2010 and 2012
Evaluation
unit
Province Province 6–7
year old popa
% of 6–7
year pop tested
N tested ICT N ICT pos % ICT pos Upper 95% exact
binomial CI
1 Torba (2010) 380 19.2% 73 0 0.0%
Sanma (2010) 1397 113.6% 1587 0 0.0%
Malampa (2010) 1207 53.3% 643 0 0.0%
Total EU1 2984 77.2% 2303 0 0.0% 0.1%
2 Penama (2010) 1034 89.9% 930 0 0.0%
Total EU2 1034 90.1% 930 0 0.0% 0.4%
3 Shefa (2010)b
(2012)
1831 5.0%
35.7%
91
653
0
0
0.0%
0.0%
Tafea (2010)b
(2012)
1,220 4.1%
37.1%
50
453
0
0
0.0%
0.0%
Total EU3 3051 40.8% 1247 0 0% 0.2%
Vanuatu total 7086 63.2% 4480 0 0%
aProjected from 1999 census
bTAS 3 in EU3 in 2010 was done in one village site in each province only (Ebule in Shefa province and Port Resolution in Tafea province)
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In 2007, during the CTS/TAS 2, an attempt was made
to determine an updated estimate and case register of
LF morbidity cases with local nurses. The teams carried
with them sufficient morbidity kits for all the previously
identified cases (care charts, basins, towels and bars of
soap) after the team members were trained in morbidity
management. At this second round of the assessment,
only 32 people with morbidity were followed up (18
males and 10 females, 4 in Sanma province with
unknown gender) compared to 95 in 2003 (Table 6);
however, it was reported that some of the survey teams
did not have time to do thorough morbidity assessment.
The cases recorded in 2007 were all above 60 years of
age, and again, the majority had limb-related morbidity
rather than hydroceles. Decrease in numbers of cases
between 2003 and 2007 was seen in all provinces, with
the biggest decrease being on Pentecost Island in
Penama province (EU2).
Availability of hydrocele surgery and numbers performed
During the period 1998 to 2006, hydrocele surgery was
available in Port Vila hospital, and an estimated 10–15
surgeries were performed during that period on
hydroceles of stages 2 to 4 [14]. After 2006, this surgery
was not available in Vanuatu until a visit by the external
surgeon in November 2015. There were at least 23
cases of hydroceles with surgical backlog, of which
eight cases were presented for examination. However,
out of these 8 patients selected by referring physicians
with a diagnosis of hydrocele, all 8 were actually con-
firmed as inguinal hernia. All were of big size, most
of them were non reducible and none was strangled.
Table 6 Morbidity data, 2003 and 2007
Province Island 2003 2007
No
cases
M F Body part affected No
cases
M F
Leg Arm Hydrocele Breast Mixed Unknown
TORBA Ureparapara 1 1 0 1
Vanualava 1 1 0 1
Total TORBA 2 2 0 1 1
SANMA Santo 15 8 7 8 1 2 4
Total SANMA 15 8 7 8 1 2 0 4 0 9 3 2
MALAMPA Ambrym 9 7 2 6 2 1 5 5
Malekula 2 2 1 1 2 2
Paama 1 1
Total MALAMPA 11 9 2 6 1 3 1 0 0 8 7 1
PENAMA Ambae 8 6 2 5 2 1
Maewo 7 5 2 6 1
Pentecost 37 18 19 26 2 6 1 2 8 5 3
Total PENAMA 52 29 23 37 2 9 2 2 0 8 5 3
SHEFA Epi 4 2 2 1 1 1 1 6 2 4
Tongoa 3 2 1 1 2
Total SHEFA 7 4 3 2 1 3 0 1 0 6 2 4
TAFEA Tanna 3 3 0 1 1 1 1 1
Erromango 5 5 0 1 4
Total TAFEA 8 8 0 2 5 0 0 1 1 1 0
VANUATU TOTAL 95 60 35 56 5 23 3 7 1 32 18 10
Table 5 Results of TAS 4 in EU2, 2012
Evaluation unit Province Province 6–7
year old popa
% of 6–7 year
pop tested
N tested ICT N ICT pos % ICT pos Upper 95% exact binomial CI
2 Penama (2012) 1034 90.2% 933 2b 0.2%
Total EU2 1034 90.2% 933 2 0.2% 0.8%
aProjected from 1999 census
bBoth were Mf negative
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While no hydrocelectomy was performed at that time,
the fact that all referred cases were hernia indicates
the need for further training in the differential diag-
nosis of hydroceles and poses the question of the real
number of remaining patients affected by “hydroceles”
out of the remaining 15 (23 minus 8) from Table 4 as
part of post-validation activities of LF morbidity
management.
Discussion and Conclusions
Vanuatu’s national CFA prevalence by ICT before
MDA in 1998 was 4.8% (N = 4362) and after MDA in
2005 was 0.2% (N = 7580) [4]. When considered by
EU, which is a combination of provinces used to de-
sign sampling frames for the C survey/TAS 1 in
2005/2006, the CFA prevalence immediately after
MDA was 0.1% in EU1 comprising Torba, Sanma and
Malampa (N = 2790 tested), 0.2% in EU2 Penama (N
= 2592 tested) and 0% in EU3 comprising Shefa and
Tafea provinces (N = 2198 tested).
This paper reports the details about monitoring
activities during the MDA and the post MDA surveil-
lance period. In the TAS 2 and 3, all three EUs passed
according to the WHO criteria. Due to concerns about
persistence of high prevalence of 3.9% in at least one
village identified in 2008, an additional TAS 4 was
conducted in Penama province only (EU2) in 2012. In
this TAS 4, EU2 passed; although there were 2 CFA
positive children discovered, the number of positives
was well below the TAS threshold. Further post valid-
ation surveillance, including antibody tests in children,
Fig. 2 Location and number of morbidity cases identified in 2003
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would be advisable especially in South Pentecost to
ensure that transmission is not persisting any longer.
The dossier summarising all the information about the
LF programme in Vanuatu was prepared in 2012 and
submitted to WHO in 2013. It was reviewed during the
13th Meeting of the Western Pacific Regional Programme
Review Group (RPRG) on neglected tropical diseases
(NTDs) in July 2013, which suggested a few modifications.
The dossier was updated accordingly and forwarded to
WHO headquarters for necessary actions in October
2014. The WHO Strategic and Technical Advisory Group
on NTDs endorsed the official process to validate elimin-
ation of LF as a public health problem in April 2015. As
per the new process, elimination of LF as a public health
problem is to be validated by the regional reviewing
authority convened by the relevant WHO Regional Office
and acknowledged by the WHO Director General. Ac-
cordingly, the Regional Dossier Review Group was con-
vened by the WHO WPRO, which reviewed the dossier of
Vanuatu and recommended validation of the claim for
Vanuatu. An official acknowledgement of accomplishment
of LF elimination as a public health problem in Vanuatu
was given by the WHO Director General and the WHO
WPRO Regional Director during the 67th session of
the Regional Committee Meeting held in Manila in
October 2016.
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